# The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?

**Authors:** Matteo Piga, Laurent Arnaud

PMC · DOI: 10.3390/jcm10020243 · 2021-01-11

## TL;DR

This paper reviews the current challenges in managing systemic lupus erythematosus, focusing on unmet needs in diagnosis, treatment, and long-term outcomes.

## Contribution

The paper outlines a research agenda to address major challenges in SLE, including early diagnosis and better treatment strategies.

## Key findings

- Early diagnosis of SLE remains a significant unmet need.
- Tailored treatment strategies could reduce organ damage and improve outcomes.
- Identifying accurate biomarkers and new therapies is crucial for better disease management.

## Abstract

Systemic lupus erythematosus (SLE) is an immune-mediated multi-systemic disease characterized by a wide variability of clinical manifestations and a course frequently subject to unpredictable flares. Despite significant advances in the understanding of the pathophysiology and optimization of medical care, patients with SLE still have significant mortality and carry a risk of progressive organ damage accrual and reduced health-related quality of life. New tools allow earlier classification of SLE, whereas tailored early intervention and treatment strategies targeted to clinical remission or low disease activity could offer the opportunity to reduce damage, thus improving long-term outcomes. Nevertheless, the early diagnosis of SLE is still an unmet need for many patients. Further disentangling the SLE susceptibility and complex pathogenesis will allow to identify more accurate biomarkers and implement new ways to measure disease activity. This could represent a major step forward to find new trials modalities for developing new drugs, optimizing the use of currently available therapeutics and minimizing glucocorticoids. Preventing and treating comorbidities in SLE, improving the management of hard-to-treat manifestations including management of SLE during pregnancy are among the remaining major unmet needs. This review provides insights and a research agenda for the main challenges in SLE.

## Linked entities

- **Diseases:** Systemic lupus erythematosus (MONDO:0007915), SLE (MONDO:0007915)

## Full-text entities

- **Genes:** IFNAR2 (interferon alpha and beta receptor subunit 2) [NCBI Gene 3455] {aka IFN-R, IFN-R-2, IFN-alpha-REC, IFNABR, IFNARB, IMD45}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}
- **Diseases:** hematologic diseases (MESH:D006402), physical inactivity (MESH:C564765), congenital heat block (MESH:C535758), COVID-19 (MESH:D000086382), organ damage (MESH:D000092124), multi-systemic disease (MESH:C000718087), leukopenia (MESH:D007970), influenza (MESH:D007251), nephritis (MESH:D009393), GCs (MESH:C564221), pain (MESH:D010146), infectious (MESH:D003141), autoimmune diseases (MESH:D001327), fetal death (MESH:D005313), atherosclerosis (MESH:D050197), antiphospholipid syndrome (MESH:D016736), Sars-Cov2 (MESH:D000094024), inflammation (MESH:D007249), musculoskeletal or renal manifestations (MESH:D009140), death (MESH:D003643), CVD (MESH:D002318), lupus nephritis (MESH:D008181), anxiety (MESH:D001007), depression (MESH:D003866), Lupus (MESH:D008180), Infections (MESH:D007239), fatigue (MESH:D005221), neonatal lupus (MESH:C536397), growth retardation (MESH:D006130), Comorbidities (MESH:D004194), infertility (MESH:D007246), Cutaneous Lupus Erythematosus Disease (MESH:D008178), mood disorders (MESH:D019964)
- **Species:** Homo sapiens (human, species) [taxon 9606], Nicotiana tabacum (American tobacco, species) [taxon 4097]
- **Mutations:** T2T

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC7827672/full.md

---
Source: https://tomesphere.com/paper/PMC7827672